Journal article : Review
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats
- Abstract:
- Through the experiences gained by accelerating new vaccines for both Ebola virus infection and COVID-19 in a public health emergency, vaccine development has benefited from a 'multiple shots on goal' approach to new vaccine targets. This approach embraces simultaneous development of candidates with differing technologies, including, when feasible, vesicular stomatitis virus or adenovirus vectors, messenger RNA (mRNA), whole inactivated virus, nanoparticle and recombinant protein technologies, which led to multiple effective COVID-19 vaccines. The challenge of COVID-19 vaccine inequity, as COVID-19 spread globally, created a situation where cutting-edge mRNA technologies were preferentially supplied by multinational pharmaceutical companies to high-income countries while low and middle-income countries (LMICs) were pushed to the back of the queue and relied more heavily on adenoviral vector, inactivated virus and recombinant protein vaccines. To prevent this from occurring in future pandemics, it is essential to expand the scale-up capacity for both traditional and new vaccine technologies at individual or simultaneous hubs in LMICs. In parallel, a process of tech transfer of new technologies to LMIC producers needs to be facilitated and funded, while building LMIC national regulatory capacity, with the aim of several reaching 'stringent regulator' status. Access to doses is an essential start but is not sufficient, as healthcare infrastructure for vaccination and combating dangerous antivaccine programmes both require support. Finally, there is urgency to establish an international framework through a United Nations Pandemic Treaty to promote, support and harmonise a more robust, coordinated and effective global response.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 304.4KB, Terms of use)
-
- Publisher copy:
- 10.1136/bmjgh-2023-011883
Authors
- Publisher:
- BMJ Publishing Group
- Journal:
- BMJ Global Health More from this journal
- Volume:
- 8
- Issue:
- 6
- Article number:
- e011883
- Place of publication:
- England
- Publication date:
- 2023-06-05
- Acceptance date:
- 2023-03-09
- DOI:
- EISSN:
-
2059-7908
- Pmid:
-
37277196
- Language:
-
English
- Subtype:
-
Review
- Pubs id:
-
1357270
- Local pid:
-
pubs:1357270
- Source identifiers:
-
W4379471480
- Deposit date:
-
2026-04-01
- ARK identifier:
Terms of use
- Copyright holder:
- Hotez et al.
- Copyright date:
- 2023
- Rights statement:
- © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use.
If you are the owner of this record, you can report an update to it here: Report update to this record